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ABSTRACT: 
 
 
Introduction:  Obesity is consistently linked with prostate cancer (PCa) recurrence and 
mortality although the mechanism is unknown.  Impaired glucose regulation, which is 
common among obese individuals, has been hypothesized as a potential mechanism for 
PCa tumor growth.   In this study we explore the relationship between serum glucose at 
time of treatment and risk of PCa recurrence following initial therapy. 
Methods:  The study group was comprised of 1,734 men treated with radical 
prostatectomy (RP) or radiation therapy (RT) for localized PCa between 2001-2010.  
Serum glucose levels closest to date of diagnosis were determined.  PCa recurrence was 
determined based on PSA progression (nadir PSA + 2 for RT; PSA ≥ 0.2 for RP) or 
secondary therapy.  Multivariate Cox regression was performed to determine whether 
glucose level was associated with BCR after adjusting for age, race, BMI, comorbidity, 
diagnosis of diabetes, Gleason Sum, PSA, treatment, and treatment year. 
Results:  Recurrence was identified in 16% of men over a mean follow-up period 41 
months (range 1 – 121 months).   Those with elevated glucose (≥ 100 mg/dL) had a 50% 
increased risk of recurrence (HR 1.5, 95% CI: 1.1-2.0) compared to those with a normal 
glucose level (< 100 mg/dL).  This effect was seen in both those undergoing RP (HR 1.9, 
95% CI 1.0–3.6) and those treated with RT (HR 1.4, 95% CI 1.0-2.0).  
Conclusion:  Glucose levels at the time of PCa diagnosis are an independent predictor of 
PCa recurrence for men undergoing treatment for localized disease.   
INTRODUCTION: 
Obesity appears to confer an increased risk of prostate cancer (PCa) specific mortality.1-6  
Considering the epidemic of obesity in the United States, understanding mechanisms 
between obesity and poor cancer prognosis holds great promise for improving patient 
outcomes.  One potential link is impaired glucose regulation, which is a precursor to 
Type II diabetes mellitus (DM), a commonly co-occurring condition with obesity.7, 8   
 
There are several pathways by which alterations in glucose metabolism may lead to 
cancer progression. Glucose is required for cancer cells for growth,9 and cancer cells are 
known to use more glucose than non-cancerous cells.   Hyperglycemia leads to elevated 
insulin levels, and the activation of the insulin/insulin-like growth factor (IGF) pathway 
has been implicated in PCa growth though positive effects on cellular proliferation and 
anti-apoptosis.10  Hyperglycemia also leads to the production of advanced glycosylated 
end products11 with resultant oxidative stress which can lead to DNA damage.  Finally, 
chronic inflammation is seen with DM and the metabolic syndrome and results in release 
of several cytokines that can promote tumor growth.12 
 
Although a diagnosis of DM (self-reported or by diagnosis code) has been associated 
with poor PCa outcomes in some studies, this finding has not been consistent.13-15  These 
mixed findings may be due to imprecision in assessment of DM, which typically uses of a 
diagnostic code and does not adequately describe the severity of DM within an 
individual.  Limited work investigated hemoglobin A1C (HbA1C)14, 16 levels as more 
specific measures of severity of DM and glucose control.  Whereas HbA1C levels are 
typically only obtained for patients with DM, glucose is a commonly collected test that is 
more widely available for analyses.  Studies in breast and colon cancer have found that 
higher blood glucose levels are associated with a greater risk of disease progression,17-19 
although such studies have not been performed in PCa.  We hypothesize that impaired 
glucose regulation, represented by higher serum glucose levels, is associated with a 
higher risk of recurrence after primary PCa treatment.  In this study we explore the 
relationship between serum glucose at time of PCa diagnosis and risk of biochemical 
recurrence (BCR) for men with localized PCa undergoing primary therapy. 
 
  
METHODS: 
Data source:  
The Northwest Veterans Integrated Services Network (VISN 20) electronic medical 
record was used to identify eligible men with PCa.  VISN 20 encompasses Washington, 
Oregon, Alaska, Idaho, western Montana and northern California and includes 7 primary 
medical centers and 27 community-based outpatient clinics.  VISN 20 uses a shared 
regional electronic medical record system and the data for this study were extracted from 
the VISN20 regional data warehouse, a system of relational databases that pulls nearly 
100% of the information contained in the electronic medical record (including clinic 
appointments, inpatient stays, pharmacy records, laboratory values, pathology reports, 
imaging tests, and vital measures).20, 21  Institution review board approval was obtained. 
 
Study population: 
We identified men diagnosed with localized prostate cancer during the years 2001 – 2010 
who were treated with either radical prostatectomy (RP) or radiation therapy (RT) in the 
form of brachytherapy or external beam radiation therapy.  We excluded men treated with 
active surveillance/watchful waiting and men with distant metastases at diagnosis.  We 
also excluded men who received primary androgen deprivation therapy (ADT) or long-
term continuous ADT as part of their primary treatment as ADT impacts glucose 
regulation.22  In order to ensure that complete follow-up would be likely within the VA 
system, we included only those men who had an established relationship with a primary 
care provider in VISN20 prior to diagnosis and had a previously assessed PSA value 
measured within the network.  
 Data collection and coding: 
The primary exposure of interest was serum glucose closest to date of diagnosis.  
Diabetes mellitus (DM) was coded based on provider recorded ICD9 diagnosis codes in 
the 12 month period prior to diagnosis. Recurrence following RP was defined as any PSA 
6 months or more after surgery ≥ 0.2 ng/mL (after achieving an undetectable PSA post-
RP).  For RT patients, PSA recurrence was defined by nadir PSA + 2.0 ng/mL.  Initiation 
of salvage therapy was also considered as evidence of progression (salvage RT, salvage 
RP or salvage ADT).  Salvage RT was defined as radiation received > 1 year after 
primary treatment date.  Several covariates were also identified from the EMR including 
demographic characteristics (age, race), clinical measures (body mass index (BMI), 
Charlson Comorbidity Index23 scores in the 12 month period prior to diagnosis) and 
tumor characteristics (year of diagnosis, Gleason score, clinical stage (available for all 
subjects), and pathologic stage (available for subjects treated with RP)).   
 
Statistical analysis: 
Descriptive statistics, including Chi-square tests, were conducted to compare 
demographic and clinical characteristics by initial treatment and by glucose level. 
Glucose level was analyzed using three different approaches.  First, quartiles of glucose 
were determined and the lowest quartile served as the referent group.  Second, the 
categories established by the American Diabetes Association (ADA) for normal (< 100 
mg/dL) impaired glucose (100 – 125 mg/dL) and diabetes (> 125 mg/dL) were used with 
the normal category serving as the referent group.  Finally, a binary analysis was 
performed using the normal ADA glucose level as the cutoff (< 100 mg/dL vs. ≥ 100 
mg/dL).  All three approaches are reported.  Patients who may have moved or stopped 
using VA care were censored at the end of the calendar year of their last visit if they had 
no VA utilization in the subsequent calendar year.  Multivariate Cox proportional hazards 
regression was performed adjusting for all covariates above (age, race, BMI, Charlson 
Comorbidity Index, year of diagnosis, treatment type, Gleason score and tumor stage) 
included in the analysis. The proportional hazards assumption was assessed by examining 
the slope of the Schoenfeld residuals. Models including all patients and stratified by 
treatment were performed.  Effect modification by treatment and by the National 
Comprehensive Cancer Network (NCCN®) risk strata24 were evaluated with the 
likelihood ratio test comparing the full model (with the interaction term) to the reduced 
model.  Two additional analyses were performed: first, excluding those with a clinical 
diagnosis of DM and/or a glucose level which would qualify for the diagnosis of DM by 
the ADA (> 125 mg/dL); and second, excluding patient with high risk disease who did 
not received concomitant ADT as this may impact risk of disease recurrence.  All 
statistical analyses were conducted using STATA software, Version 12 (Stata, Inc., 
College Station, TX). 
  
RESULTS: 
 
A total of 1,734 men were identified during the study period undergoing treatment with 
either RP (n = 722) or RT (n = 1,012).  Table 1 presents the demographic and pathologic 
features of these men by disease recurrence status.  As expected, pathologic factors (PSA, 
Gleason and stage were highly associated with recurrence.  Several differences between 
men undergoing RP or RT were identified (data not shown).  Men treated with RT were 
older (15% vs. 1% over age 75, p<0.001) had higher Charlson Comorbidity scores 
(p<0.001) and were more likely to have been diagnosed with DM prior to diagnosis 
(p<0.001).  Men receiving RT had higher pretreatment PSA values compared to the RP 
group (35% ≥ 10 ng/mL vs. 19%, p<0.001).  The median follow-up time was 41 months 
(range 1 – 121 months).   Recurrence was observed in 281 men (16%). Cumulative 
recurrence was similar following RT (15%) and surgery (17%).  Recurrence events 
occurred in 7%, 14% and 33% of low, intermediate and high risk cases (as defined by the 
National Comprehensive Cancer Network (NCCN®)),24 respectively.   
 
Table 2 shows the distribution of demographic and pathologic features by different ADA 
glucose levels.  A total of 514 (30%), 623 (36%) and 597 (34%) had glucose levels of < 
100, 100-125 and > 125 mg/dL, respectively.  Men in the highest glucose category were 
more commonly obese, with higher Charlson scores and having a diagnosis of diabetes 
mellitus (all p < 0.001).  Gleason sum scores of 7-10 were more common in the highest 
category of glucose (68%) compared to 57% and 59% for the lower two categories, 
respectively (p = 0.001).  Similarly, higher clinical stage (T2b-T3) was more common in 
those with glucose > 125 mg/dL (23%) than those with lower glucose levels (16 and 17% 
respectively, p = 0.04).  Surgery was more common in those with the highest glucose 
levels.  
 
The hazard ratios (HR) and 95% CI for risk of recurrence by quartile of glucose level are 
presented in Table 3 for the entire cohort.  The lowest quartile (range 31 – 98 mg/dL) 
served as the referent group in the multivariate analysis adjusting for age, race, BMI, 
diagnosis of DM, treatment type and year of treatment, stage, Gleason and Charlson 
Score.  In the overall cohort, we observed a modest trend in increased risk (range 35 – 
57%) of recurrence for each of the glucose quartiles compared to the lowest quartile, 
although this was not significant.  There was no evidence for effect modification by 
treatment or NCCN risk category (both likelihood ratio test p-value > 0.6).  In the RP 
group, all three higher quartiles had a more than 2-fold increased risk of recurrence 
compared to the lowest quartile, with p-values ranging from 0.01 to 0.04, data not 
shown).  In the RT group, there were non-significant differences in risk of recurrence 
with higher glucose levels (range 18 – 48%).  The risk of recurrence by the three ADA 
glucose categories is presented in Table 4 along with dichotomous ADA categories.   In 
the entire cohort, those with an abnormal glucose (> 100mg/dL) had a 46% increased risk 
of recurrence (HR: 1.46: 95% CI 1.09 – 1.95).  This observed risk was present in both the 
RP group (HR 1.91, 95% CI 1.03 – 3.55) and the RT group (HR 1.42, 95% CI 1.00 – 
2.01).  Excluding those with either a clinical diagnosis of DM or a serum glucose which 
would qualify for the diagnosis of DM by the ADA (> 125 mg/dL) did not change the 
results.  In that analysis including both RP and XRT patients, having a glucose of 100-
125 mg/dL was associated with a 44% increased risk of recurrence compared to those 
with a normal glucose level (HR 1.41, 95% CI 1.01 –1.97).  
  
DISCUSSION: 
 
In this study, we found that men with elevated glucose levels at the time of PCa diagnosis 
have a greater risk of PCa recurrence following primary treatment compared to men with 
a normal glucose level.  Considering the growing obesity epidemic and the consistent 
relationship between obesity and adverse PCa outcomes,7, 8 these findings are important 
in helping to identify modifiable risk factors for men undergoing treatment for newly 
diagnosed PCa. 
 
Glucose and cancer outcomes have been evaluated in breast and colorectal cancer.17-19, 25  
In a study of 202 women with breast cancer, there was a similar increased risk of 
recurrence in the 2nd (HR 1.9, 95% CI 1.1-3.2) and 3rd (HR 1.8 (95% CI 1.0-3.1) tertiles 
compared to the lowest tertile.17  In colorectal cancer, those with the highest quartile of 
glucose (HR 1.8, 95% CI 1.1-3.1)19 or post load plasma glucose (HR 1.6, 95% CI 1.1-
2.4)18 had higher risk of disease-specific mortality compared to those in the lowest 
quartile.  These studies support the role of abnormal glucose regulation and cancer 
outcomes. 
 
Small studies have evaluated serum biomarkers of glucose regulation and PCa.  In a 
study of 89 men with DM treated with RP, a higher HbA1C pre-operatively was 
associated with the risk of extracapsular disease (pT3) and higher Gleason grade (≥ 7).26  
In another study of 247 men undergoing RP, HbA1C levels pre-operatively were 
associated with higher Gleason grade (p = 0.001).16   Higher HbA1C levels were 
associated with a non-significant risk of recurrence:  compared to those with HbA1C < 
6.3, the HR for men with HbA1C of 6.3-7.7 and ≥ 7.8 was 1.5 (95% CI 0.8-2.6) and 1.3 
(0.7-2.4), respectively.16  Both of these studies are limited by their small size and only 
including men with DM.   Studies have found associations between insulin levels and 
PCa-specific mortality.1, 27  In one study, a higher mean fasting insulin level at diagnosis 
was found in those who died of PCa.27  In a second study, levels of C-peptide (an insulin 
surrogate) were determined from PCa cases from the Physicians Health Study.1  Those in 
the highest C-peptide quartile had a more than 2-fold increased risk of PCSM (HR 2.4, 
95% CI 1.3 – 4.3) compared to those in the lowest C-peptide quartile.   We do not have 
insulin or C-peptide levels available in our study and thus rely on serum glucose levels as 
an indicator of an individual’s glucose regulation. 
 
The present analysis is the first to specifically evaluate glucose levels and outcomes in 
men with PCa.  We found that men with an elevated glucose at the time of PCa diagnosis 
had an almost 50% increased risk of PCa recurrence even after adjusting for clinical and 
pathologic factors.  Whether it is hyperglycemia, or subsequent elevated levels of 
insulin/IGF, which affect tumor recurrence cannot be determined from this study.  
Studies have not found a significant relationship between the diagnosis of DM (self-
reported or diagnosis code)13-15 and PCa recurrence, but the diagnosis of DM may not 
reflect an individual’s current glycemic control.  This could lead to misclassification as 
men with well controlled DM may have glucose and insulin levels similar to men without 
DM and vice-versa.  Thus, using a serum biomarker is more sensitive for accurately 
determining the relationship between glucose regulation and disease outcomes.  Our 
analysis is also unique in that we include both surgical and radiation patients.  Although 
the magnitude of influence with hyperglycemia on recurrence is less in the XRT group, 
the direction of the effect is the same and there was no evidence for effect modification 
by treatment.  Potential reasons for this attenuation include regression to the mean, 
differences in BCR definitions, unmeasured confounding and the concomitant use of 
ADT in the radiation group alone. 
 
There are limitations to our study.  We only use a single glucose measurement which may 
not reflect an individual’s ongoing glucose regulation during their post-treatment time.  A 
hemoglobin A1C measurement does represent one’s recent glucose regulation, however 
such values were only available in those with DM, and similar to the pre-operative 
glucose level, will not necessarily reflect subsequent glucose regulation. Further, we 
cannot be certain that these glucose levels were drawn fasting, however the median 
glucose for men without the diagnosis of DM was 107 (interquartile range 96 – 126).  
Data from the Center for Disease Control and Prevention Diabetes Fact Sheet 2011, state 
that 35% of adults over aged 20 (and 50% of adults over the age of 65) had prediabetes 
based on fasting glucose levels.28  Thus our data, in which 72% of the patients are over 
age 60 years and 82% of patients are overweight or obese, are consistent with this 
distribution.  Our population reflects Veterans who are consistent users of VA care and 
may not be generalizable to other men.  Because the VA is an open system, some men 
may go to non-VA providers for follow-up care which may not get reported back to the 
VA. This appears to happen infrequently, a prior study of men with elevated PSA tests, 
8% of men received subsequent care outside of the VA,29 and we specifically restricted 
our cohort to men who had an established primary care relationship prior to diagnosis to 
help reduce this potential limitation. Our definitions of biochemical recurrence may 
misclassify some men as not having evidence of recurrence and we cannot rule out Type 
1 error in this analysis.  We also do not include medication usage for treatment of DM 
which may impact glucose levels and we cannot rule out additional sources of 
unmeasured confounding.  Future study of medication usage for DM may be informative.  
Finally, recurrence after PCa is a heterogeneous event with many individuals not 
progressing to PCa-specific mortality (PCSM).  Although PCSM is a more robust 
endpoint, we did not have enough events to study this relationship.  Use of national VA 
data in the future may allow such an analysis. 
 
In conclusion, men with an elevated glucose level at the time of treatment for localized 
PCa have a higher risk of recurrence than men with a normal glucose level. This analysis 
provides evidence that disease progression may be influenced by glucose, suggesting that 
glucose control could be a modifiable risk factor for PCa recurrence and progression.   
  
 Table 1.  Demographic and Tumor Characteristics of Men Treated for 
Localized Prostate Cancer by Disease Recurrence Status 
 Disease Recurrence  
 No 
N (%) 
Yes 
N (%) 
P – value* 
Age     
   < 65 815 (84) 154 (16) 0.11 
   65 – 74 509 (85) 91 (15)  
   ≥ 75 129 (78) 36 (22)  
Race    
   Caucasian 1,231 (84) 236 (16) 0.69 
   African-American 124 (82) 28 (18)  
   Other 98 (85) 17 (15)  
Year of Diagnosis    
   2001 – 2003 317 (78) 88 (22) < 0.001 
   2004 – 2006 499 (82) 112 (18)  
   2007 – 2010 637 (89) 81 (11)  
BMI    
   < 25 240 (81) 57 (19) 0.11 
   25 – 29 589 (83) 121 (17)  
   ≥ 30 620 (86) 103 (14)  
Charlson Score    
   None 636 (84) 119 (16) 0.61 
   1 426 (85) 78 (15)  
   2 – 3  263 (82) 58 (18)  
   ≥ 4 102 (81) 24 (19)  
Diabetes Mellitus    
   No 1,127 (83) 223 (17) 0.51 
   Yes  326 (85) 58 (15)  
Diagnostic PSA    
   < 4.0 132 (90) 14 (10) < 0.001 
   4.0 – 9.9 940 (86) 153 (14)  
   10 – 19.9 311 (80) 76 (20)  
   ≥ 20 70 (65) 38 (35)  
Gleason Sum    
   6 602 (90) 65 (10) < 0.001 
   7 643 (85) 115 (15)  
   8 – 10  201 (67) 101 (33)  
Clinical T-stage    
   T1 – T2a 1,198 (85) 207 (15) < 0.001 
   T2b – T2c 239 (80) 60 (20)  
Treatment    
   Surgery 596 (83) 126 (17) 0.23 
   Radiation 857 (85) 155 (15)  
* p-value for Chi-2 test between surgery and radiation 
  
Table 2.  Demographic and Tumor Characteristics of Men Treated for Localized Prostate 
Cancer Stratified by American Diabetes Association Serum Glucose Categories 
 Glucose Level  
 < 100 mg/dL 
N (%) 
100-125 mg/dL 
N (%) 
> 125 mg/dL 
N (%) 
P – value* 
Age      
   < 65 256 (50) 349 (56) 364 (61) <0.001 
   65 – 74 190 (37) 218 (35) 192 (32)  
   ≥ 75 68 (13) 56 (9) 41 (7)  
Race     
   Caucasian 433 (84) 524 (84) 510 (85) 0.49 
   African-American 42 (8) 54 (9) 56 (9)  
   Other 39 (8) 45 (7) 31 (5)  
Year of Diagnosis     
   2001 – 2003 133 (26) 155 (25) 117 (20) 0.004 
   2004 – 2006 198 (39) 198 (32) 215 (36)  
   2007 – 2010 183 (36) 270 (43) 265 (44)  
BMI     
   < 25 109 (21) 110 (18) 78 (13) <0.001 
   25 – 29 243 (47) 255 (41) 212 (36)  
   ≥ 30 162 (32) 256 (41) 305 (51)  
Charlson Score     
   None 255 (50) 289 (47) 211 (36) <0.001 
   1 143 (28) 289 (28) 187 (32)  
   2 – 3  82 (16) 113 (18) 126 (21)  
   ≥ 4 28 (6) 35 (6) 63 (10)  
Diabetes Mellitus      
   No 460 (89) 541 (87) 349 (58) <0.001 
   Yes  54 (11) 82 (13) 248 (42)  
Diagnostic PSA     
   < 4.0 37 (7) 51 (8) 58 (10) 0.1 
   4.0 – 9.9 307 (60) 406 (65) 380 (64)  
   10 – 19.9 138 (27) 130 (21) 119 (20)  
   ≥ 20 32 (6) 36 (6) 40 (7)  
Gleason Sum     
   6 217 (43) 258 (42) 192 (32) 0.001 
   7 220 (43) 259 (42) 279 (47)  
   8 – 10  73 (14) 104 (17) 125 (21)  
Clinical T-stage     
   T1 – T2a 429 (83) 516 (83) 460 (77) 0.04 
   T2b – T2c 78 (15) 95 (15) 126 (21)  
   T3+ 7 (1) 12 (2) 11 (2)  
Treatment     
   Surgery 105 (20) 246 (39) 371 (62) <0.001 
   Radiation  409 (80) 377 (61) 226 (38)  
* p-value for Chi-2 test - 
  
 
  
Table 3:  Adjusted Risk of Prostate Cancer Recurrence  
by Quartiles of Serum Glucose 
  
Quartile 
 
Range 
(mg/dL) 
N Events (%) Overall HR (95% CI)* 
1st 31 – 98 464 61 (13) 1.00 (referent) 
2nd 99 – 111 416 68 (16) 1.35 (0.95 -- 1.92) 
3rd 112 – 137 414 76 (18) 1.57 (1.10 – 2.24) 
4th 138 – 1015 438 76 (17) 1.44 (0.97 – 2.14) 
*HR adjusted for age, race, body mass index, diagnosis of diabetes, 
treatment year, treatment, clinical stage, diagnostic PSA, Gleason Sum 
 
Table 4:  Risk of Recurrence after Prostate Cancer Treatment 
by American Diabetes Association Serum Glucose Categories 
  N Events N (%) HR (95% CI)* 
3 Categories    
    < 100 mg/dL 445  69 (13) 1.00 (referent) 
   100 – 125 mg/dL 513 110 (18) 1.50 (1.10 – 2.04) 
   > 125 mg/dL 495 102 (17) 1.36 (0.95 -- 1.95) 
      
     
2 Categories    
   < 100 mg/dL 445 69 (13) 1.00 (referent) 
   ≥ 100 mg/dL 1006 212 (17) 1.46 (1.09 -- 1.95) 
*HR adjusted for age, race, body mass index, diagnosis of diabetes, 
treatment year, treatment, clinical stage, diagnostic PSA, Gleason 
Sum 
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